Alli Return In U.S. Fattens Glaxo’s Consumer Outlook
This article was originally published in The Pink Sheet Daily
Executive Summary
GSK Consumer Healthcare says alli would be available starting Feb. 25 in most stores in the U.S. and Puerto Rico in “improved tamper-evident packaging.” Despite the product’s checkered history, its return marks another boost for Glaxo’s consumer outlook.
You may also be interested in...
New York's Halt On Sales To Minors Could Catch More Than Weight Loss, Bodybuilding Products
“What are retailers going to do? They're either going to put it behind a case or they're going to put it in a pharmacy-only counter where you have to ask for assistance to get it,” says CRN CEO Steve Mister. “Until we have some more insight, we're being over inclusive in terms of what we're including,” says attorney Claudia Lewis.
Little Innovation In US OTC Switches For 20 Years, ACNU Won't Remove Impediments – Study
Of 45 switches since 2002, three added an indication to OTC market and three were “an exceptional innovation” offering “a genuinely novel OTC product, providing a new to OTC active pharmaceutical ingredient, pharmacological class, and indication,” Haleon researchers found.
Alli Recall Could Help Mitigate Reputation Damage In Face Of Tampering
GSK investigates tampering with its alli weight-loss drug and positions itself as a consumer advocate with a U.S. recall of the product. By showing it is “on the side of good” the firm could actually emerge from the crisis with a stronger reputation, says crisis management expert Gene Grabowski says.